A 72-year-old man on mechanical ventilation for 8 days develops hospital-acquired pneumonia (HAP). Sputum culture is pending. He has no recent antibiotic exposure. What is the most appropriate empirical antibiotic regimen?

Explanation

## Empirical Therapy for Hospital-Acquired Pneumonia (HAP) **Key Point:** HAP requires broad-spectrum coverage targeting gram-negative organisms (including *Pseudomonas aeruginosa*), *Staphylococcus aureus*, and anaerobes. Empirical regimens differ from CAP based on nosocomial pathogen epidemiology. ### Risk Stratification for HAP **High-Yield:** The patient has **early-onset HAP** (day 8 of ventilation, no recent antibiotics): - Lower risk for multidrug-resistant (MDR) pathogens - Still requires coverage of *Pseudomonas* and *Staphylococcus aureus* - Standard empirical regimen: **Antipseudomonal beta-lactam ± fluoroquinolone or aminoglycoside** ### Recommended Empirical Regimens for HAP | Regimen | Spectrum | Use Case | |---------|----------|----------| | **Piperacillin-tazobactam** | Gram-negative (including *Pseudomonas*), gram-positive, anaerobes | First-line for early HAP | | **Cefepime** | Gram-negative (including *Pseudomonas*), gram-positive | First-line for early HAP | | Cefepime/Piperacillin-tazobactam + fluoroquinolone (levofloxacin) | Enhanced gram-negative + atypical coverage | Enhanced empirical coverage | | Cefepime/Piperacillin-tazobactam + aminoglycoside (gentamicin) | Synergistic gram-negative coverage | Enhanced empirical coverage | | Ceftriaxone monotherapy | Limited gram-negative spectrum | **Inadequate for HAP** — lacks *Pseudomonas* coverage | | Amoxicillin-clavulanate | Limited to community organisms | **Not appropriate for HAP** | **Clinical Pearl:** The addition of a fluoroquinolone or aminoglycoside to the antipseudomonal beta-lactam provides: 1. Dual coverage of *Pseudomonas aeruginosa* (synergistic effect) 2. Enhanced gram-negative spectrum 3. Improved outcomes in severe HAP ### Why This Patient Qualifies for Standard (Not Enhanced) Regimen **Mnemonic: "EARLY HAP" Risk Factors for MDR** — **E**arly onset (< 5 days), **A**ntibiotics (no recent use), **R**espiratory (not on ventilator long), **L**ow severity, **Y**oung age (relative). This patient has **low risk** for MDR organisms, so standard antipseudomonal beta-lactam ± adjunct therapy is appropriate. **Note:** If high-risk features present (late-onset HAP, prior antibiotics, immunosuppression, severe illness), broader coverage including carbapenem or anti-MRSA agents (vancomycin, linezolid) would be indicated. [cite:Harrison 21e Ch 297]